Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response.
DNA repair gene
cell‐free DNA
gene panel
immune checkpoint inhibitor
tumor mutational burden
Journal
Clinical & translational immunology
ISSN: 2050-0068
Titre abrégé: Clin Transl Immunology
Pays: Australia
ID NLM: 101638268
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
02
2020
revised:
24
04
2020
accepted:
19
05
2020
entrez:
4
7
2020
pubmed:
4
7
2020
medline:
4
7
2020
Statut:
epublish
Résumé
Immune checkpoint inhibitors (ICIs) have become the standard of care in various cancers, although the predictive tool is still unknown. This study aimed to develop a novel gene panel by selecting DNA damage response (DDR) genes from the Catalogue of Somatic Mutations in Cancer (COSMIC) databank and validating them in previously reported cohorts. This association between DDR gene mutations and tumor mutation burden or microsatellite status was analysed from The Cancer Genome Atlas (TCGA) databank. Furthermore, we made the gene panel clinically accessible and predicted the response in clinical patients receiving ICIs by using cell-free DNA. The top 20 mutated DDR genes in various cancers (total 37 genes) were taken from the COSMIC databank, and the DDR genes found to individually predict a response rate > 50% in Van Allen's cohort were selected ( This gene panel is a novel and reliable tool for predicting the response to ICIs in cancer patients and guides the appropriate administration of ICIs in clinical practice.
Identifiants
pubmed: 32617161
doi: 10.1002/cti2.1145
pii: CTI21145
pmc: PMC7326616
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e1145Informations de copyright
© 2020 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
N Engl J Med. 2014 Dec 4;371(23):2189-2199
pubmed: 25409260
Lancet. 2016 May 7;387(10031):1909-20
pubmed: 26952546
N Engl J Med. 2010 Aug 19;363(8):711-23
pubmed: 20525992
Nat Rev Mol Cell Biol. 2010 Mar;11(3):220-8
pubmed: 20177397
Oncologist. 2019 Oct;24(10):1340-1347
pubmed: 31040255
J Clin Oncol. 2018 Mar 10;36(8):773-779
pubmed: 29355075
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758
pubmed: 30787022
Nat Rev Cancer. 2019 Mar;19(3):133-150
pubmed: 30755690
Ann Oncol. 2019 Apr 1;30(4):582-588
pubmed: 30715153
Cell Syst. 2018 Mar 28;6(3):271-281.e7
pubmed: 29596782
Clin Cancer Res. 2019 Dec 1;25(23):7035-7045
pubmed: 31383735
Science. 2015 Apr 3;348(6230):124-8
pubmed: 25765070
Science. 2015 Oct 9;350(6257):207-211
pubmed: 26359337
Oncotarget. 2016 Apr 26;7(17):23312-21
pubmed: 27004405
Sci Rep. 2015 Aug 26;5:13321
pubmed: 26306458
Clin Cancer Res. 2019 Dec 1;25(23):7024-7034
pubmed: 31506389
Cell. 2016 Mar 24;165(1):35-44
pubmed: 26997480
Nat Genet. 2006 Sep;38(9):1043-8
pubmed: 16921376
Lancet Oncol. 2017 Sep;18(9):1182-1191
pubmed: 28734759
Cancer Immunol Res. 2018 Oct;6(10):1122-1128
pubmed: 30279188
Transl Lung Cancer Res. 2018 Dec;7(6):668-677
pubmed: 30505711
Lancet Oncol. 2018 Nov;19(11):1480-1492
pubmed: 30361170
Cancer Cell. 2018 May 14;33(5):853-861.e4
pubmed: 29731394